Key result
Genetic testing in cardiomyopathies aids risk stratification and prognostication but is limited by VUS.
Genetic testing is an important tool for risk stratification and prognostication in cardiomyopathies, though its clinical utility can be complicated by variants of unknown significance.
Requires cautious interpretation in clinical practice due to VUS; leaves open standardization of variant classification in cardiomyopathy research.
PURPOSE OF REVIEW: As rapid genetic testing has become increasingly accessible in a timely fashion, more genetic mutations are identified in inherited conditions such as cardiomyopathies. Understanding when to consider genetic testing is an important part of the management of patients whose presentations vary from decompensated heart failure to sudden cardiac death. RECENT FINDINGS: We describe the benefits of genetic testing for risk stratification of family members, prognostication of probands, and identification of novel disease-causing mutations and examine the possible role of genetic predisposition in seemingly acquired cardiomyopathies such as peripartum and anthracycline-induced cardiomyopathy. SUMMARY: Genetic screening for the recognition of family members who have inherited a cardiomyopathy is important, and testing may identify patients at higher risk of sudden death. However, genetic testing does have its limitations, such as the identification of variants of unknown significance that often complicate the clinical picture.
No takes yet. Share an insight, caveat, or question.
Aleksova et al. (2016) conducted a review in Cardiomyopathies. Genetic testing was evaluated. Genetic testing in cardiomyopathies aids in risk stratification of family members and prognostication of probands, but is limited by the identification of variants of unknown significance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: